- Home
- NTHI vs ACRS Comparison
NTHI vs ACRS Comparison
Compare NTHI & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTHI
- ACRS
- Stock Information
- Founded
- NTHI 2008
- ACRS 2012
- Country
- NTHI United States
- ACRS United States
- Employees
- NTHI N/A
- ACRS 64
- Industry
- NTHI Biotechnology: Pharmaceutical Preparations
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- NTHI Health Care
- ACRS Health Care
- Exchange
- NTHI Nasdaq
- ACRS Nasdaq
- Market Cap
- NTHI 142.5M
- ACRS 137.5M
- IPO Year
- NTHI N/A
- ACRS 2015
- Fundamental
- Price
- NTHI $7.24
- ACRS $1.46
- Analyst Decision
- NTHI
- ACRS Strong Buy
- Analyst Count
- NTHI 0
- ACRS 8
- Target Price
- NTHI N/A
- ACRS $9.71
- AVG Volume (30 Days)
- NTHI 108.1K
- ACRS 709.4K
- Earning Date
- NTHI 01-01-0001
- ACRS 05-08-2025
- Dividend Yield
- NTHI N/A
- ACRS N/A
- EPS Growth
- NTHI N/A
- ACRS N/A
- EPS
- NTHI N/A
- ACRS N/A
- Revenue
- NTHI $79,990.00
- ACRS $17,777,000.00
- Revenue This Year
- NTHI N/A
- ACRS N/A
- Revenue Next Year
- NTHI N/A
- ACRS $14.59
- P/E Ratio
- NTHI N/A
- ACRS N/A
- Revenue Growth
- NTHI 13.52
- ACRS N/A
- 52 Week Low
- NTHI $4.11
- ACRS $0.99
- 52 Week High
- NTHI $25.00
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- NTHI N/A
- ACRS 61.33
- Support Level
- NTHI N/A
- ACRS $1.22
- Resistance Level
- NTHI N/A
- ACRS $1.56
- Average True Range (ATR)
- NTHI 0.00
- ACRS 0.09
- MACD
- NTHI 0.00
- ACRS 0.03
- Stochastic Oscillator
- NTHI 0.00
- ACRS 75.00
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.